SynAct Pharma
SynAct Pharma AB is a Swedish clinical-stage biopharmaceutical company focused on the development of selective melanocortin receptor agonists for the treatment of inflammatory diseases. The company utilizes its proprietary drug development platform to advance therapeutic candidates, such as apabetalone and resomelagon, designed to resolve inflammation by stimulating natural resolution mechanisms rather than purely immunosuppressive pathways. Its clinical pipeline addresses severe autoimmune and inflammatory conditions, including rheumatoid arthritis and inflammatory bowel disease. Core operations encompass preclinical pharmacology, biomarker research, and clinical trial advancement. As a clinical-stage research firm, the company generates minimal commercial revenue and finances its operations through capital market offerings and partner collaborations. SynAct Pharma holds an emerging position in targeted anti-inflammatory drug discovery. The company is headquartered in Lund, Sweden, and its shares trade on Nasdaq Stockholm.
3 of the funds FundTelligence covers report a position in SynAct Pharma.
- Legal name
- SynAct Pharma AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 3
Funds holding SynAct Pharma
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Småbolag Plus — Storebrand · 0.03 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)